‘Preclinical trials show that BL-7050 offers favorable properties from the perspective of bioavailability, efficacy and safety.’ ‘Persistent neuropathic or inflammatory discomfort is a leading reason behind disability and probably the most common factors patients go to a family doctor,’ stated Dr. Kinneret Savitsky, CEO of BioLineRx. ‘The neuropathic pain marketplace, which reached $2.4 billion in the seven main markets in ’09 2009, is saturated with therapeutics that usually do not offer a satisfactory solution, because of either small efficacy or unacceptable unwanted effects, and there exists a clear dependence on new, better treatments.’.. BioLineRx, Tel Aviv University indication license agreement to build up and commercialize BL-7050 BioLineRx , a biopharmaceutical advancement company, today announced that it has signed an internationally, exclusive license contract with Ramot in Tel Aviv University Ltd., the technology transfer organization of Tel Aviv University, for the advancement and commercialization of BL-7050, a novel, orally-obtainable treatment for inflammatory and neuropathic pain.Ph.D college student Astrid Drivsholm Sloth, who conducted today’s study, characterizes the procedure as promising and predicts that it has widespread potential in the treating heart attacks. However, larger research are needed confirm the medical implications of the smaller pilot trial in a way that it could be clarified whether the fresh intervention can decrease mortality and the advancement of heart failing after a coronary attack.
PRESS RELEASE CAMBRIDGE, Mass. & GAINESVILLE, Fla.—-BiogenandAGTC today announced a wide collaboration and permit agreement to build up gene-based therapies for multiple ophthalmic diseases.